Losmapimod Did Not Benefit Patients with Facioscapulohumeral Muscular Dystrophy | Docwire News
Losmapimod failed to show clinical benefit over placebo in FSHD patients in the phase 3 REACH trial, ending its development.
Related Articles
Subscribe | Docwire News
Sign up for DocWire News eNewsletters to get the latest medical industry news and expert insights and to join an extensive community of health care…
Cases Demonstrate Utility of Prophylactic Eculizumab in SCD | Docwire News
Two cases of patients with SCD and history of delayed hemolytic transfusion reaction were presented at EHA2025.
Novel Interferon-Based Agent Compares Favorably with Anagrelide in Essential Thrombocythemia | Docwire News
The SURPASS ET trial evaluated efficacy and safety of ropeginterferon alfa-2b in second-line ET treatment.
Associations Between Sleep Patterns and Disorders in Patients on Hemodialysis | Docwire News
In an observational study, patients receiving hemodialysis who reported shorter sleep duration or problems sleeping had a higher mortality risk.
Outcomes With Finerenone Among Patients With Acute Changes in eGFR | Docwire News
A study showed that finerenone had kidney and cardiovascular benefits for patients with chronic kidney disease (CKD) even after an acute eGFR change occurred.
Study Supports Exa-cel’s Potential as SCD Cure | Docwire News
The analysis was an assessment of 15-year follow-up data from the CLIMB study and was presented at EHA2025.
How TikTok Shapes IBD Conversations | Docwire News
None of the popular videos included content from healthcare providers.
Dose Escalation Study Data Support Novel Calreticulin-Mutation-Targeting Antibody for High-Risk ET | Docwire News
The study data presented at EHA2025 were from patients who had disease resistant to prior therapy or intolerance to therapy.
Risk of Cardiovascular Mortality Varies With CKM Stage | Docwire News
Higher cardiovascular mortality risk was associated with higher cardiovascular-kidney-metabolic (CKM) syndrome stage, research showed.
FDA Issues Fast Track Designation to Oral PIM1 Kinase Inhibitor for Myelofibrosis | Docwire News
The FDA previously granted Orphan Drug Designation to nuvisertib for use in myelofibrosis in May 2022.